@article{AltieriLaSalviaModicaetal.2023,
  author    = {Altieri, Barbara and La Salvia, Anna and Modica, Roberta and Marciello, Francesca and Mercier, Olaf and Filosso, Pier Luigi and de Latour, Bertrand Richard and Giuffrida, Dario and Campione, Severo and Guggino, Gianluca and Fadel, Elie and Papotti, Mauro and Colao, Annamaria and Scoazec, Jean-Yves and Baudin, Eric and Faggiano, Antongiulio},
  title     = {Recurrence-free survival in early and locally advanced large cell neuroendocrine carcinoma of the lung after complete tumor resection},
  series = {Journal of Personalized Medicine},
  volume    = {13},
  journal   = {Journal of Personalized Medicine},
  number    = {2},
  issn      = {2075-4426},
  doi       = {10.3390/jpm13020330},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-304000},
  year      = {2023},
  abstract  = {Background: Large Cell Neuroendocrine Carcinoma (LCNEC) is a rare subtype of lung cancer with poor clinical outcomes. Data on recurrence-free survival (RFS) in early and locally advanced pure LCNEC after complete resection (R0) are lacking. This study aims to evaluate clinical outcomes in this subgroup of patients and to identify potential prognostic markers. Methods: Retrospective multicenter study including patients with pure LCNEC stage I-III and R0 resection. Clinicopathological characteristics, RFS, and disease-specific survival (DSS) were evaluated. Univariate and multivariate analyses were performed. Results: 39 patients (M:F = 26:13), with a median age of 64 years (44-83), were included. Lobectomy (69.2\%), bilobectomy (5.1\%), pneumonectomy (18\%), and wedge resection (7.7\%) were performed mostly associated with lymphadenectomy. Adjuvant therapy included platinum-based chemotherapy and/or radiotherapy in 58.9\% of cases. After a median follow-up of 44 (4-169) months, the median RFS was 39 months with 1-, 2- and 5-year RFS rates of 60.0\%, 54.6\%, and 44.9\%, respectively. Median DSS was 72 months with a 1-, 2- and 5-year rate of 86.8, 75.9, and 57.4\%, respectively. At multivariate analysis, age (cut-off 65 years old) and pN status were independent prognostic factors for both RFS (HR = 4.19, 95\%CI = 1.46-12.07, p = 0.008 and HR = 13.56, 95\%CI 2.45-74.89, p = 0.003, respectively) and DSS (HR = 9.30, 95\%CI 2.23-38.83, p = 0.002 and HR = 11.88, 95\%CI 2.28-61.84, p = 0.003, respectively). Conclusion: After R0 resection of LCNEC, half of the patients recurred mostly within the first two years of follow-up. Age and lymph node metastasis could help to stratify patients for adjuvant therapy.},
  language  = {en}
}
@article{HerbertHirzleBartmannetal.2023,
  author    = {Herbert, Saskia-Laureen and Hirzle, Paula and Bartmann, Catharina and Schlaiß, Tanja and Kiesel, Matthias and Curtaz, Carolin and L{\"o}b, Sanja and W{\"o}ckel, Achim and Diessner, Joachim},
  title     = {Optimized process quality in certified breast centers through adherence to stringent diagnostic and therapeutic algorithms effects of structural as well as socio-demographic factors on start of therapy},
  series = {Archives of Gynecology and Obstetrics},
  volume    = {307},
  journal   = {Archives of Gynecology and Obstetrics},
  number    = {4},
  doi       = {10.1007/s00404-022-06666-2},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-324057},
  pages     = {1097-1104},
  year      = {2023},
  abstract  = {Purpose An increasing incidence of breast cancer can be observed worldwide. Since a delay of therapy can have a negative impact on prognosis, timely cancer care is an important quality indicator. By receiving treatment at a certified breast cancer center, the patient has the best chance of treatment in accordance with guidelines and the best prognosis. The identification of risk factors for a delay of therapy is of central importance and should be the basis for a continuous optimization of treatment at breast cancer centers. Methods This retrospective study included women with breast cancer (primary diagnosis, relapse, or secondary malignancy) at the University Hospital W{\"u}rzburg in 2019 and 2020. Data were retrieved from patients' records. Correlations and regression analyses were performed to detect potential risk factors for treatment delay. Results Patients who received the histological confirmation of breast cancer at an external institution experienced a later therapy start than those patients who received the histological confirmation at the University Hospital W{\"u}rzburg itself. (35.7 vs. 32.2 days). The interval between histological confirmation and the first consultation at the University Hospital W{\"u}rzburg correlated statistically significant with age, distress and distance to the hospital. Conclusion Patients with an in-house diagnosis of breast cancer are treated more quickly than those whose diagnosis was confirmed in an external institution. We identified factors such as increased age, greater distance to the hospital as well as increased distress to prolong the time until start of oncological treatment. Intensified patient care should be offered to these subgroups.},
  language  = {en}
}
@article{SchulmeyerFaschingHaeberleetal.2023,
  author    = {Schulmeyer, Carla E. and Fasching, Peter A. and H{\"a}berle, Lothar and Meyer, Julia and Schneider, Michael and Wachter, David and Ruebner, Matthias and P{\"o}schke, Patrik and Beckmann, Matthias W. and Hartmann, Arndt and Erber, Ramona and Gass, Paul},
  title     = {Expression of the immunohistochemical markers CK5, CD117, and EGFR in molecular subtypes of breast cancer correlated with prognosis},
  series = {Diagnostics},
  volume    = {13},
  journal   = {Diagnostics},
  number    = {3},
  issn      = {2075-4418},
  doi       = {10.3390/diagnostics13030372},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-304987},
  year      = {2023},
  abstract  = {Molecular-based subclassifications of breast cancer are important for identifying treatment options and stratifying the prognosis in breast cancer. This study aimed to assess the prognosis relative to disease-free survival (DFS) and overall survival (OS) in patients with triple-negative breast cancer (TNBC) and other subtypes, using a biomarker panel including cytokeratin 5 (CK5), cluster of differentiation 117 (CD117), and epidermal growth factor receptor (EGFR). This cohort-case study included histologically confirmed breast carcinomas as cohort arm. From a total of 894 patients, 572 patients with early breast cancer, sufficient clinical data, and archived tumor tissue were included. Using the immunohistochemical markers CK5, CD117, and EGFR, two subgroups were formed: one with all three biomarkers negative (TBN) and one with at least one of those three biomarkers positive (non-TBN). There were significant differences between the two biomarker subgroups (TBN versus non-TBN) in TNBC for DFS (p = 0.04) and OS (p = 0.02), with higher survival rates (DFS and OS) in the non-TBN subgroup. In this study, we found the non-TBN subgroup of TNBC lesions with at least one positive biomarker of CK5, CD117, and/or EGFR, to be associated with longer DFS and OS.},
  language  = {en}
}
@phdthesis{Stefenelli2023,
  author    = {Stefenelli, Ulrich},
  title     = {Der „W{\"u}rzburger Herz-Score", ein Modell zur tageweisen Vorhersage des Sterberisikos in den ersten 4 Wochen nach Herzklappen- oder Bypass-Operation bei 5555 Patienten},
  doi       = {10.25972/OPUS-30382},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-303828},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2023},
  abstract  = {Bei 5555 Patienten des W{\"u}rzburger Zentrums f{\"u}r operative Medizin wurden Sterberisiken und assoziierte Faktoren nach Bypass- oder Aortenklappen-OP beschrieben. Eine Risikovorhersage war fr{\"u}hzeitig, sogar tageweise m{\"o}glich, und nicht (wie bisher) mit Blick auf den 30. postoperativen Tag. Das st{\"a}rkste Risiko ist ein fehlender Entlassungs-Sinusrhythmus, gefolgt von einer schweren pr{\"a}operativen Einschr{\"a}nkung (ASA) und einem erh{\"o}hten Kreatinin, gefolgt vom kardiogenen anamnestischen Schock, vom zerebrovaskul{\"a}ren Ereignis, der Notwendigkeit von Frischplasma, von einer respiratorischen Insuffizienz, aber auch der Notwendigkeit mechanischer Kreislaufunterst{\"u}tzung. Hochpr{\"a}diktiv war auch ein k{\"u}rzlich stattgefundener Myokardinfarkt und eine Angina Pectoris in Ruhe. Liegen bis 4 dieser Ereignisse vor, so zeigt sich das Mortalit{\"a}tsrisiko als statistisch normal (Verlauf der Grundgesamtheit): Es steigt je Woche nach OP um etwa 1\% auf rund 5\% nach 4 Wochen an. Bestehen 5 oder 6 Risiken, so erh{\"o}ht sich das Sterberisiko deutlich: Es steigt um +10\% je weitere Woche an und erreicht etwa 40\% in der 4. postoperativen Woche. Ab 7 oder mehr erf{\"u}llte Risiken nimmt das Sterberisiko drastisch zu. Es erh{\"o}ht sich um +20\% je weitere Woche und kumuliert nach 3 Wochen auf rund 70\%. Festzuhalten ist: Bis 4 Risiken ergibt sich je weitere Woche +1\% Mortalit{\"a}tsrisiko, ab 5 Risikofaktoren +10\%, ab 7 und mehr Risikofaktoren finden sich je Woche nach der OP ein um +20\% erh{\"o}htes Sterberisiko. Diese Erkenntnisse wurden verwendet, um einen Risikoscore zu konstruieren. Die Einzelrisiken werden summiert, d.h. man betrachtet das Risiko als erf{\"u}llt oder nicht, und z{\"a}hlt. Das tageweise Risiko ist graphisch ablesbar und ist f{\"u}r die klinische Routine verwendbar, f{\"u}r Studien (Risikostratifizierung) oder f{\"u}r das pr{\"a}operative Aufkl{\"a}rungsgespr{\"a}ch. Neu ist, dass dieser Score im klinischen Verlauf angepaßt werden kann, wenn neue Risikofaktoren auftreten hinzukommen oder Faktoren therapiebedingt wegfallen.},
  subject      = {{\"U}berleben},
  language  = {de}
}